

# Research Journal of Pharmaceutical, Biological and Chemical Sciences

## Detection Of Carbapenamase Production Among MDR *Acinetobacter* Species Isolated From Clinical Samples.

Sacin Wankhede<sup>1</sup>, Apurva<sup>2\*</sup>, Sunil B Bhamare<sup>3</sup>.

<sup>1</sup>Professor and HOD, Microbiology Department, Smt. Kashi Bai Navale Medical College And General Hospital, Pune, Maharashtra, India.

<sup>2</sup>Senior Resident, Microbiology Department, AIIMS, Patna, Bihar, India.

<sup>3</sup>Associate Professor, Microbiology Department, BJGMC, Pune, Maharashtra, India.

### ABSTRACT

Increasing antimicrobial resistance especially carbapenem resistance worldwide is a concern as it limits the range of alternative agents. *Acinetobacter* species, a gram-negative bacterium commonly found in hospital environment and hospitalized patients, is causing various nosocomial infections with increasing resistance by producing carbapenamase. This descriptive study was carried out at Department of Microbiology of a tertiary care hospital from Jan 2018 to June 2019. In this period, total 9475 samples were received in laboratory from wards, OPDs and ICUs and processed based on standard conventional methods and out of these samples, 300 *Acinetobacter* species were isolated by standard biochemical tests. The antibiotic sensitivity testing is done by Kirby Bauer Disc Diffusion method using Muller Hinton agar. Carbapenamase production is tested by using Rapidec Carba NP test. It is found that this infection is common in extremes of age groups like neonates of preterm deliveries and patients of age over 45 years associated with other conditions. Out of these isolates, 73% of Imipenem resistant *Acinetobacter* isolates were carbapenamase producers and 281 (93.66%) *Acinetobacter* isolates were from wards. This study will help to understand the emerging threat of multidrug resistance and help physicians to select most accurate and appropriate antibiotic treatment.

**Keywords:** Carbapenamase , MDR *Acinetobacter* species , clinical samples

<https://doi.org/10.33887/rjpbcs/2023.14.1.11>

*\*Corresponding author*

## INTRODUCTION

According to the World Health Organization (WHO), worldwide over 1.4 million people at any given time suffer from infectious complication acquired from hospitals [1, 2]. An important consequence of Hospital Acquired Infections (HAIs) is the increasing antimicrobial resistance due to tremendous antimicrobial pressure, especially in ICUs [3]. A vicious cycle of 'more infections, more antimicrobial use, followed by development of multidrug resistant bacterial infections and use of still higher generation antimicrobial' is seen in many hospitals. There has been increasing incidence of *Acinetobacter* species causing serious nosocomial infections which are being reported worldwide. *Acinetobacter* species is the 2<sup>nd</sup> most frequent non fermenter encountered in clinical laboratories and is one of the common causative pathogens for late onset hospital acquired pneumonia [4].

Since last 30 years, strains of *A. baumannii* have acquired resistance to newly developed antimicrobials. Carbapenems remains the treatment of choice if isolates are sensitive to this class. Unfortunately, carbapenem-resistant *Acinetobacter* isolates are increasingly reported throughout the world as Efflux pumps may affect Meropenem, whereas specific  $\beta$ -lactamases hydrolyse Imipenem [5].

*A.baumannii* has transformed from being susceptible to most of the antimicrobial three decade ago to currently being pan drug resistant including carbapenems, colistin, and tigecycline. New mechanisms of resistance acquired by *Acinetobacter baumannii*, along with other gram negative pathogens is due to plasmids, integrons, and transposons. Production of enzymes are also resistance mechanism common to *A. baumannii* and other gram negative bacteria [6]. Genes coding for these enzymes can be transferred from cell to cell via transposons. For penicillins, cephalosporins, and carbapenems a common enzyme is  $\beta$ -lactamase, which hydrolyzes and confers resistance to these drugs. Mutated genes like VIM, IMP, and OXA can also be transferred from other bacteria which ultimately alter bacterial targets of antimicrobials leading to decrease in affinity for the bacteria and increasing the minimum inhibitory concentration (MIC) for the drug [6].

Thus, the main objective of this study is to isolate *Acinetobacter species* from various clinical samples by phenotypic method and study their resistance pattern to 1st line and 2nd line (including carbapenem) antibiotics by Kirby-Bauer disk diffusion method and know the prevalence of Carbapenemase production in *Acinetobacter species* resistant to carbapenem by Rapidec Carba NP Test.

## MATERIALS AND METHODS

The study was carried out at Department of Microbiology of a tertiary care hospital from Jan 2018 to June 2019.

**Study design:** Descriptive study

**Material:** *Acinetobacter species* were isolated from various clinical samples from hospitals. The various clinical samples were pus, blood, urine, body fluid, sputum, throat swab, and swab from surgical, non-surgical wound tissue. These samples were collected from patients of all age groups and both sexes admitted in outpatient and various inpatient departments of tertiary care hospital.

**Sample size:** The study includes 300 isolates of *Acinetobacter species* from various clinical samples during the period of Jan 2018 to June 2019.

### Methods

Presumptive identification of *Acinetobacter* was done by phenotypic method and was put through battery of tests:


- 1) Hanging drop for motility
- 2) Study of cultural characteristics on:-
  - Blood Agar
  - MacConkey Agar
- 3) For production of enzymes
  - Catalase

- Oxidase
- Urease
- 4) For substrate utilization
  - Citrate test
- 5) For metabolism of proteins and amino acids
  - Indole production test
- 6) Utilization of carbohydrates
  - Exhibits rapid utilization of 1% Glucose and 10% Lactose with production of acid
- 8) Antibiotic sensitivity testing by Kirby Bauer disc diffusion test for
  - 1<sup>st</sup> line drugs: Amikacin (30µg), Cefotaxime (30µg), Gentamicin (10µg), Co-Trimoxazole (1.25/23.75µg), Doxycycline (30µg), Ciprofloxacin (5µg)
  - 2<sup>nd</sup> line drugs: Imipenem (10µg), Piperacilin- tazobactam (100/10µg).
- 9) Carbapenemase production in Acinetobacter species- resistant to carbapenem (Imipenem) by Rapidec Carba NP Test.

**RESULTS**

- During 18 months of study period from Jan 2018 to June 2019, a total of 9475 specimens were examined from patient of different age group; admitted in various medical, surgical wards, ICU and were included in this study.
- Distribution of Samples examined and number of *Acinetobacter species* isolated from various samples is illustrated in Figure 1.

**Table/Figure-1**




**Table/Figure-2**

**Number Of Acinetobacter Isolated From Various Samples During Study Period**

Specimen	Acinetobacter	Percentage (%)
1) Pus / swab	104	34.66%
2) Urine	61	20.33%
3) Sputum	56	18.66%
4) Blood	10	3.33%
5) CSF	2	0.66%
6) Tracheal aspirate/endotracheal tube tip	67	22.33%
<b>TOTAL</b>	<b>300</b>	<b>100%</b>

- A total of 300 isolates of Acinetobacter species were isolated during the study period.
- Highest isolation of Acinetobacter was from pus / swab sample followed by tracheal aspirate or Endo-tracheal tip and urine.


Table/Figure-3



- Male: Female ratio 1.4: 1.
- Acinetobacter infection was more common in patients over 45 years of age.
- Most of these patients had respiratory problems like chronic obstructive pulmonary disease (COPD), bronchial asthma, respiratory failure, and other predisposing factors like diabetes mellitus, cellulitis, surgical site infection, chronic renal failure, liver cirrhosis, and immunosuppression.
- Infection in neonates was common in preterm babies.

Table/Figure-4

Ward Wise Distribution Of Acinetobacter Isolates



- Number of Acinetobacter isolates was more from surgical wards followed by ICU.
- Most of the isolates from paediatric ward were from preterm babies.
- Others include samples from Orthopedic, Obstetric, Ent, Skin etc wards.

Table/Figure-5

Sensitivity Pattern Of Acinetobacter Isolates To Different Antibiotics

Antibiotics	Sensitive (S)	Intermediate Sensitive (IS)	Resistance (R)
Amikacin(Ak)	89	4	207
Cefotaxime(Ctx)	18	1	281
Gentamicin(G)	85	1	214
Co-trimoxazole(Sxt)	78	0	222
Doxycycline(Do)	100	0	200
Ciprofloxacin(Cip)	62	1	237
Imipenem(Imp)	77	4	219
Piperillin-tozabactum(Ptz)	58	3	239

Table/Figure-6

**Carbapenemase production in resistant *Acinetobacter* isolates**

Imipenem			Carbapenemase producers (Rapidec Carba NP)
Sensitive	Intermediate	Resistant	
77(25.66%)	4(1.33%)	219(73%)	219

- 73% of Imipenem resistant *Acinetobacter* isolates were carbapenemase producers.

**DISCUSSION**

*Acinetobacter species* are emerging as agents of opportunistic nosocomial infection with evolving drug resistance very rapidly and has become a real problem in hospital set-up, particularly in the critical care units [7]. *Acinetobacter species* are now one of the most common organisms isolated from hospital environments and hospitalized patients [8]. Especially carbapenem-resistant *Acinetobacter species* are increasingly recognized as major hospital acquired pathogens, in patients with critical illnesses or in intensive care. These organisms have the capability to accumulate diverse mechanisms of resistance thus limits the available antimicrobial agents. Making the treatment difficult for infection, and is associated with increased risk of mortality [9].

Present study was conducted in a tertiary care hospital and total of 9475 samples were collected and studied [Figure1]. Out of these specimens 300 isolates were *Acinetobacter species*, which were studied for their antimicrobial susceptibility [Table 1]. *Acinetobacter species* isolated accounted for 3.16% of total culture. Similar study was conducted by Mindolli PB et al in 2010 *Acinetobacter* isolates accounted for 4.25% of total number of organisms isolated during study period [10]. Study done during 1971-81 in United States, *Acinetobacter species* accounted for 1.4% of all infections. Higher percentage in this study i.e. 3.16% *Acinetobacter species* may be due to better identification scheme. This also shows the role of *Acinetobacter* as nosocomial pathogen since in most cases patients were symptomatic with fever, leucocytosis, urinary tract infection (UTI). In another study conducted by Joshi et al in Mumbai in 2006, *Acinetobacter* isolation rate was 9.6% [11]. Huang CH et al observed that high prevalence can probably be related to non-compliance with the recommendations for hospital infection control policy [12]. Fishbain J et al reported that higher prevalence can be due to lack in hands hygiene and misuse of antibiotics [13]. Since hand transmission is a major factor in the spread of this pathogen,<sup>12</sup> hand hygiene and disinfection of equipment/environment are the two most important factors to control and prevent the outbreak of an epidemic *Acinetobacter*.

In this study 281 (93.66%) *Acinetobacter* isolates were from inpatient departments (IPD) and 19 (6.33%) were from outpatient departments (OPD). In the study conducted by Rebic V et al prevalence was more among the inpatients (98%), which clearly reflects the nosocomial origin of this pathogen [14]. Prevalence of *Acinetobacter* in the review done by Manchanda V et al [15] was 85% (ICUs), 60% (medical wards), and 59% (surgical wards) and they have summarized the sources for colonization or infection with multidrug-resistant *Acinetobacter species* in hospitalized patients which are:-

- Hands of the hospital staff
- Respiratory therapy equipment
- Food (including hospital food)
- Tap water
- Infusion pumps
- Mattresses, pillows, bed curtains and blankets in vicinity of infected patients
- Soap dispensers
- Fomites like bed rails, stainless steel trolleys, door handles, telephone handles, tabletops
- Hospital sink traps
- Hospital floor

All these factors could be the risk factor in this study also as majority of the isolates were from inpatient departments.

*Acinetobacter* infections were more common in age group 61 & above (22%), followed by age group 21-30yr (17.33%) and age group 51-60yr (15.66%) in this study [Figure 2]. In the study conducted by Rebic V et al, the proportion of isolates was more in the age group over 60(44.60%) [14]. Uwingabiye J et al observed 31.3% were above 65 years having *Acinetobacter* infections [16]. These patients had underlying predisposing factors like COPD, diabetes mellitus, renal failure, liver cirrhosis and were on prior antibiotic therapy. Turkoglu M et al in their study observed that old age of patients is as an independent risk factor of the acquiring *Acinetobacter* infections [17]. Lower immunity with predisposing chronic condition leading to longer duration of hospital stay justifies the infection rate to be common in old age. Neonates suffering from septicaemia showed 6.66% of septicaemia was due to *Acinetobacter* spp in the present study. Vinodkumar C S et al in Karnataka observed that 8.9% babies showed septicaemia due to *Acinetobacter* species [18]. Most of the isolates, from paediatric age group were from preterm babies and septicaemic patients. The use of antibiotics probably alters the normal flora and result in selection of microorganisms like *Acinetobacter* species.

Isolation rate was highest from pus sample 34.66%, majority of them were from cellulitis and wound infections [Table/Figure-7].

Isolation rate from blood in this study was 3.33%; most of them were from preterm and septicaemic patients. While study done by Mindolli PB et al [10] from JJM Medical College Davangere, Karnataka isolation of *Acinetobacter* from blood was 2.9%.

Studies of *Acinetobacter* from various countries as shown in Table given below have shown predominance of isolation from urine (21-27%), tracheobronchial secretions (24.8-48.8%). In the present study *Acinetobacter* was isolated from urine (20.33%), tracheobronchial secretions (22.33%), and sputum (18.66%).

*Acinetobacter* species isolation from various countries [19].

*Acinetobacter baumannii* in Spain (1999-2005) in a study conducted by Asensio A et al was isolated maximum from respiratory tract (42.2%) followed by surgical wound (15.1%), urinary tract (12.9%), skin (11.7%) [20]. Another study by Joshi et al in 2006 from King Edward Memorial Hospital, Mumbai *Acinetobacter* isolated from urine was 30.6% and 27.5% were isolated from samples in case of wound infection [11].

There were two isolate from CSF (cerebrospinal fluid) both were from intensive care unit suffering from meningitis. One of them was 6 months female from PICU another was 56 years male from MICU.

Most of the isolates were from surgical wards 76 isolates (25.33%), followed by MICU 39 (13%), medicine ward 35 (11.66%) who had undergone invasive procedures like intravascular catheterization, urinary tract catheterization, mechanical ventilation, prior surgery etc [Figure 3]. This corresponds to the study done by Cisneros JM et al [36] and Siegman IY et al [21]. Study conducted by Cisneros JM et al reported 56 patients (71%) were in an ICU, 13 (16%) were being treated in medical wards, and 10 (13%) were in surgical wards at the time of the bacteremic episode. These findings were in concordance with the study done by Mindolli PB et al where most of the isolates were from surgical wards 61 isolates (30.5%), ICU 54 isolates (27%) and paediatric ward 38 isolates (19%). In a study conducted by Anupurba S et al in 2005, 20.8% of *Acinetobacter* were isolated from ICU, whereas in the present study it was 37.33% which shows the increasing trend of *Acinetobacter* to cause nosocomial infections.

One of the most striking features of genus *Acinetobacter* is the ability to develop antibiotic resistance extremely rapid in response to challenge with new antibiotics. As noted by the Infectious Disease Society of America, *Acinetobacter* is "a prime example of mismatch between unmet medical need and the current antimicrobial research and development pipeline [22]. *Acinetobacter* species are notorious for their ability to acquire antibiotic resistance to most available antibiotics including broad spectrum cephalosporins and fluoroquinolones. Reports on carbapenemase-producing *Acinetobacter* isolates are on rise globally due to increased carbapenem usage and selection pressure [23].

In this study, out of the 300 *Acinetobacter* isolates, strains showed 69% resistant to Amikacin by disc diffusion method [Table 2]. Similar study by Joshi SG et al<sup>11</sup> also reported resistant to Amikacin was

68.6%. Others studies by Sinha N et al from a tertiary care setting in North India [6] reported 84.8% resistance to Amikacin in Meropenem sensitive cases. Patwardhan RB et al [24] and Mohammad R et al [25] reported high level resistance to Amikacin i.e. 96.2% and 85.2% respectively.

Resistant to Cefotaxime is 93.6% in this study [Table 2]. Similarly 90.6% was reported by Mohammad R et al [25], 100% was seen by Patwardhan RB et al [24], 89.3% was observed by Sinha N et al [26], 95.4% resistance was reported by Joshi SG et al[11].

Present study shows that the strains were resistant to Gentamicin in 71.33% cases [Table 2], 85.2% by Mohammad R et al [25], 85.7% by Sinha N et al [26], 96.2% was seen by Patwardhan RB et al [24].

Resistant to Co-trimoxazole in this study is 74% [Table 2]. 68.2% was reported by Mohammad R et al [25].

Resistant to Doxycycline in this study is 66.66% [Table 2]81.3% was observed by Sinha N et al<sup>26</sup>, 88.5% by Patwardhan RB et al [24].

In this study strains were resistant to Ciprofloxacin in 79% cases, 72.9% cases were resistant to Ciprofloxacin by Joshi SG et al [11]. High level resistance were observed by Sinha N et al [26], Mohammad R et al [25] and Patwardhan RB et al [24] i.e. 85.7%, 90.9% and 96.2% respectively.

Piperacillin-tazobactam showed 79.66% resistance in isolated cases. 42% was observed by Mohammad R et al [25]. Higher percentage 92.3% was reported by Patwardhan RB et al [24] may be due readily transferable antibiotic resistance expressed by *Acinetobacter*. They have the ability to acquire resistance to many major classes of antibiotics [27].

In the present study, Imipenem showed 73% resistant. Shakibaie MR et al from Iran reported resistance percentage of 73.3% to imipenem [28].

The above findings clearly show the emerging resistance to co-trimoxazole and ciprofloxacin followed by imipenem and increased level of resistance to piperacillin-tazobactam, and third-generation cephalosporins. These drugs remain the main stay of treatment for *Acinetobacter infections* and are usually reserved for severely ill patients. In order to prevent resistance and for antibiotic stewardship and rapid implementation of outbreak control measures, rapid detection of carbapenemase producers provides critical information [29]. The use of the Rapidec Carba NP test may allow to the identify carbapenemase producers and improve infection control [30].

Various modalities are available for the rapid identification of carbapenemase producers<sup>31</sup>

1.	UV spectrophotometry [32]
2.	Matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) technology [33-35]
3.	Molecular techniques [36-38]

These modalities have good sensitivities and specificities but have disadvantages like

- Require trained microbiologists
- Expensive equipment
- In addition, if carbapenemase genes are not included in the given gene panel or unknown carbapenemase genes, molecular techniques may fail to detect [39].

A rapid and biochemical detection of carbapenemase production was used in this study, namely The Rapidec Carba NP test. All carbapenem resistant isolates came out to be positive for carbapenemase production by Rapidec Carba NP test [Table 3]. It has excellent specificity and sensitivity, allowing reliable detection of known carbapenemases in *Acinetobacter species* [39].

## CONCLUSIONS

*Acinetobacter* species has recently emerged as one of the most important opportunistic nosocomial pathogens. *Acinetobacter* species is frequently isolated in hospitals and have been involved in a number of outbreaks in ICUs. It has posed detrimental effects in terms of increase in length of hospital stay, financial burden and mortality rate. There is a need for strict adherence to surveillance programs in order to prevent the colonization, the infection, and the dissemination of this pathogen. Antimicrobial treatment of multidrug-resistant pathogens presents an increasing challenge to patient care. Clinicians are bound to use an unusual combination of drugs, in the hope that it may be efficacious. The increasing trend of MDR isolates to higher generation cephalosporins and Carbapenems is a problem as it leaves no option but use of colistin as the last alternative. Since there is lack of data on antimicrobial surveillance, study on antimicrobial resistance surveillance is the need of the hour. It will help the centres to generate local antibiogram which will helps in having a national data. It also guides the clinicians to choose appropriate empirical therapy as well as assist in escalation and de-escalation whenever possible. Hence this study can help in establishing antimicrobial stewardship and regulate the antimicrobial use.

#### REFERENCES

- [1] WHO: Guidelines on Prevention and Control of Hospital Associated Infections. World Health Organization. South East Asian Region. Geneva: WHO;2002.
- [2] Weinstein RA. Nosocomial infection update. *Emerg Infect Dis*. 1998 Jul-Sep;4(3): 416–420.
- [3] Kollef MH. Optimizing antibiotic therapy in the intensive care unit setting. *Crit Care*. 2001;5(4):189–195.
- [4] Chastre J, Fagon JY. Ventilator-associated pneumonia. *Am J Respir Crit Care Med*. 2002 Apr;165(7):867-903.
- [5] Maragakis LL, Perl TM. *Acinetobacter baumannii*: epidemiology, antimicrobial resistance, and treatment options. *Clin Infect Dis*. 2008Apr;46(8):1254-63.
- [6] Camp C, Tatum OL. A Review of *Acinetobacter baumannii* as a Highly Successful Pathogen in Times of War. *Laboratory Medicine*. November 2010;41(11):649–57.
- [7] Bhattacharyya S, Bhattacharyya I, Rit K, Mukhopadhyay PK, Dey JB, Ganguly U et al. Antibiogram of *Acinetobacter* spp. isolated from various clinical specimens in a tertiary care hospital in West Bengal, India. *Biomedical Research*. 2013;24(1).
- [8] Fournier PE, Richet H. The epidemiology and control of Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant *Acinetobacter* Infections *Acinetobacter baumannii* in health care facilities. *Clin Infect Dis*. 2006;42:692-9.
- [9] Kim UJ, Kim HK, An JH, Cho SK, Park KH, Jang HC. Update on the Epidemiology, Treatment, and Outcomes of Carbapenem-resistant *Acinetobacter* infections. *Chonnam Med J*. 2014 Aug;50(2):37–44.
- [10] Mindolli P.B, Manjunath P.S, Vishwanath G, Hanumanthappa A.R. Identification and Speciation Of *Acinetobacter* And Their Antimicrobial Susceptibility Testing. *Al Ameen J Med Sci*. 2010;3(4):345-349.
- [11] Joshi SG, Litake GM, Satpute MG, Telang NV, Ghole VS, Niphadkar KB. Clinical and demographic features of infection caused by *Acinetobacter* species. *Indian J Med Sci*. 2006 Sept; 60(9):351-60.
- [12] Huang CH, Lee CL, Lin ACM, Chen WY, Teng PC, Lee SH, Hsieh YJ, Jang TN. Different strains of *Acinetobacter baumannii* spreading in an intensive care unit. *JACME*. 2011;1:5–10.
- [13] Fishbain J, Peleg AY. Treatment of *Acinetobacter* Infections. *Clin Infect Dis*. 2010;51(1):79–84.
- [14] Rebic V, Masic N, Teskeredzic S, Aljicevic M, Abduzaimovic A, Rebic D. The Importance of *Acinetobacter* Species in the Hospital Environment. *Med Arch*. 2018 Nov;72(5):325–329.
- [15] Manchanda V, Sinha S, Singh NP. Multidrug Resistant *Acinetobacter*. *J Glob Infect Dis*. 2010 Sep-Dec;2(3):291–304.
- [16] Uwingabiye J, Mohammed F, Lemnouer A, Bssaibis F, Belefquih B, Maleb A, Dahraoui S et al. *Acinetobacter* infections prevalence and frequency of the antibiotics resistance: comparative study of intensive care units versus other hospital units. *Pan Afr Med J*. 2016;23:191.
- [17] Turkoglu M, Mirza E, Tunçcan ÖG, Erdem GU, Dizbay M, Yağcı M et al. *Acinetobacter baumannii* infection in patients with hematologic malignancies in intensive care unit: risk factors and impact on mortality. *J Crit Care*. 2011 Oct;26(5):460-467.
- [18] Vinodkumar CS, Neelagund YF. *Acinetobacter* septicaemia in neonates. *Indian J Med Microbiol*. 2004;22:71.
- [19] Lahiri KK, Mani NS, Purai SS. *Acinetobacter* spp as Nosocomial pathogen: Clinical significance and antimicrobial sensitivity. *Med J Armed Forces of India* 2004;60:7-10.



- [20] Asensio A, Canton R, Vague J, Calbo-Torrecillas F, Herruzo R, Arribas JL et al. Prevalence of infection by carbapenem resistant *A. baumannii* in Spain (1999-2005). *Enferm Infecc Microbiol Clin*. 2008 April;26(4):199-204.
- [21] Siegman-Igra Y, Bar Yosef S, Gorea A, Avram J. Nosocomial *Acinetobacter meningitis* secondary to invasive procedures: Report of 25 cases and review. *Clin Infect Dis*. 1993;17:843-49.
- [22] Coelho JM, Turton JF, Kaufmann ME, Glover J, Woodford N, Warner M et al. Occurrence of carbapenem-resistant *Acinetobacter baumannii* clones at multiple hospitals in London and Southeast England. *J Clin Microbiol*. 2006;44:3623-3627.
- [23] Taneja N, Singh G, Singh M, Sharma M. Emergence of tigecycline and colistin resistant *Acinetobacter baumannii* in patients with complicated urinary tract infections in north India. *Indian J Med Res*. 2011;133:681-4.
- [24] Patwardhan R.B, Dhakephalkar P.K, Niphadkar K.B, Chopade B.A. A study on nosocomial pathogens in ICU with special reference to multiresistant *Acinetobacter baumannii* harbouring multiple plasmids. *Indian J Med Res*. August 2008;178-187.
- [25] Rahbar M, Mehrgan H, Aliakbari NH. Prevalence of antibiotic-resistant *Acinetobacter baumannii* in a 1000-bed tertiary care hospital in Tehran, Iran. *Indian J Pathol Microbiol*. 2010;53:290-3.
- [26] Sinha N, Agarwal J, Srivastava S, Singh M. Analysis of carbapenem-resistant *Acinetobacter* from a tertiary care setting in North India. *Indian J Med Microbiol* 2013;31:60-3.
- [27] Bergogne-Berezin E. The increasing role of *Acinetobacter* species as a nosocomial pathogen. *Curr Infect Dis Rep* 2001;3:440-4.
- [28] Shakibaie MR, Adeli S, Salehi MH. Antibiotic resistance patterns and extended spectrum beta-lactamase production among *Acinetobacter* spp. isolated from an intensive care Unit of a hospital in Kerman, Iran. *Antimicrob Resist Infect Control*. 2012;1:1.
- [29] Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! *Trends Mol Med*. 2012;18:263-272.
- [30] Poirel L, Nordmann P. Rapidec Carba NP Test for Rapid Detection of Carbapenemase Producers. *J Clin Microbiol*. 2015;53(9):3003-3008.
- [31] Dortet L, Brécharde L, Cuzon G, Poirel L, Nordmann P. Strategy for rapid detection of carbapenemase-producing Enterobacteriaceae. *Antimicrob Agents Chemother*. 2014;58:2441-2445.
- [32] Bernabeu S, Poirel L, Nordmann P. Spectrophotometry-based detection of carbapenemase producers among Enterobacteriaceae. *Diagn Microbiol Infect Dis*. 2012;74:88-90.
- [33] Hrabák J, Walková R, Studentová V, Chudácková E, Bergerová T. Carbapenemase activity detection by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *J Clin Microbiol*. 2011;49:3222-227.
- [34] Kempf M, Bakour S, Flaudrops C, Berrazeg M, Brunel JM, Drissi M et al. Rapid detection of carbapenem resistance in *Acinetobacter baumannii* using matrix-assisted laser desorption ionization-time of flight mass spectrometry. *PLoS One*. 2012;7:31676.
- [35] Lee W, Chung HS, Lee Y, Yong D, Jeong SH, Lee K et al. Comparison of matrix-assisted laser desorption ionization-time of-flight mass spectrometry assay with conventional methods for detection of IMP-6, VIM-2, NDM-1, SIM-1, KPC-1, OXA-23, and OXA-51 carbapenemase-producing *Acinetobacter* spp., *Pseudomonas aeruginosa*, and *Klebsiella pneumoniae*. *Diagn Microbiol Infect Dis*. 2013;77:227-30.
- [36] Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. *Diagn Microbiol Infect Dis*. 2011;70:119-23.
- [37] Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S et al. Multiplex PCR for genes encoding prevalent OXA carbapenemases in *Acinetobacter* spp. *Int J Antimicrob Agents*. 2006;27:351-53.
- [38] Hofko M, Mischnik A, Kaase M, Zimmermann S, Dalpke AH. Detection of carbapenemases by real-time PCR and melt curve analysis on the BD Max system. *J Clin Microbiol*. 2014;52:1701-704.
- [39] Poirel L, Nordmann P. Rapidec Carba NP Test for Rapid Detection of Carbapenemase Producers. *J Clin Microbiol*. 2015;53(9):3003-3008.